Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration

Abstract Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss i...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2011-08, Vol.188, p.135-141
Main Authors: Fontanilla, C.V, Ma, Z, Wei, X, Klotsche, J, Zhao, L, Wisniowski, P, Dodel, R.C, Farlow, M.R, Oertel, W.H, Du, Y
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Blotting, Western
Brain - drug effects
Brain - metabolism
Brain - pathology
Caffeic Acids - pharmacology
CAPE
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Fundamental and applied biological sciences. Psychology
Immunohistochemistry
Male
Medical sciences
Mice
Mice, Inbred C57BL
mitochondria
MPTP
MPTP Poisoning - metabolism
MPTP Poisoning - pathology
Nerve Degeneration - metabolism
Nerve Degeneration - pathology
Nerve Degeneration - prevention & control
Neurology
Neuroprotective Agents - pharmacology
Parkinson's disease
Phenylethyl Alcohol - analogs & derivatives
Phenylethyl Alcohol - pharmacology
Vertebrates: nervous system and sense organs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+ -induced neurotoxicity in vitro and directly inhibited MPP+ -induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2011.04.009